<!doctype html>
<html lang="en">
  <head>
    <!-- Required meta tags -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <!-- Swiper CSS -->
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/swiper@11/swiper-bundle.min.css" />
    <!-- CSS -->
    <link rel="stylesheet" href="assets/css/index.css">
    <style>
      a.pink_link{
        padding-top:10px;
      }
    </style>
    <script type="text/javascript" src="https://cdn.jsdelivr.net/npm/lozad/dist/lozad.min.js"></script>

    <title>Maze CT</title>
  </head>
  <body>
    <header>
      <div class="container">
        <div class="right">
          <button class="btn_menu">
            <svg id="Layer_2" data-name="Layer 2" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 62.72 53.93">
              <defs>
                <style>
                  .cls-1 {
                    fill: none;
                    stroke: #00edd5;
                    stroke-linecap: round;
                    stroke-miterlimit: 10;
                    stroke-width: 6px;
                  }
                </style>
              </defs>
              <g id="page1">
                <g id="Menu_icon" data-name="Menu icon">
                  <line class="cls-1" x1="3" y1="26.97" x2="59.72" y2="26.97"/>
                  <line class="cls-1" x1="3" y1="3" x2="23.44" y2="3"/>
                  <line class="cls-1" x1="39.28" y1="3" x2="59.72" y2="3"/>
                  <line class="cls-1" x1="3" y1="50.93" x2="23.44" y2="50.93"/>
                  <line class="cls-1" x1="39.28" y1="50.93" x2="59.72" y2="50.93"/>
                </g>
              </g>
            </svg>
          </button>
        </div>
      </div>
      <nav id="menu">
        <div class="close">
          <a href="#"><img class="lozad" data-src="assets/images/close.svg" alt="close icon"></a>
        </div>
        <ul>
          <li><a href="#apol1_origin">APOL1 AND ITS ORIGIN</a></li>
          <li><a href="#apol_kidney">APOL1 Kidney Disease</a></li>
          <li><a href="#recognizing_symptoms">RECOGNIZING SYMPTOMS</a></li>
          <li><a href="#apol1_gene">You, Your Family, and the APOL1 Gene</a></li>
          <li><a href="#mazes_commitment">Maze's Commitment to You </a></li>
          <li><a href="#advisary_committee">Maze Patient Advisory
            Committee</a></li>
          <li><a href="#learn_more">Learn More About 
            APOL1 Kidney Disease 
            and MZE829</a></li>
          <li><a href="#maze_affliations">Maze Patient Advocacy Affiliations</a></li>
        </ul>
      </nav>
    </header>
    <section class="section bg" id="hero" >
      <div class="container">
        <div class="text">
          <div class="middle">
            <a href="/"><img class="lozad" data-src="assets/images/header-logo.png" alt="Maze Logo"></a>
          </div>
          <h1>
           <span class="brand">Explore, Educate, </span>and <span class="brand">Empower</span><br> yourself to manage APOL1 Kidney Disease
          </h1>
          <!-- <a class="pink_link" href="#">[text]</a> -->
        </div>
      </div>
    </section>

    <section id="slider_nav">
      <div class="container">
        <img class="lozad bg" data-src="assets/images/slider-bg.png" alt="slider background object" >
        <p class="heading">Take charge of your <span class="brand">kidney</span> health!</p>
        <div class="swiper">
          <div class="swiper-wrapper">
            <div class="swiper-slide">
              <div class="img" style="border-color: #710cc4;" >
                <a href="#apol1_origin"><img class="lozad" data-src="assets/images/apol-1-and-its-origin.jpg" alt="APOL1 AND ITS ORIGIN"></a>
                <div class="text">
                  <a class="pink_link" href="#apol1_origin">APOL1 AND ITS ORIGIN</a>
                </div>
              </div>
              <p>Learn about the APOL1 gene and how it increases your risk of getting chronic kidney disease</p>
            </div>
            <div class="swiper-slide">
              <div class="img" style="border-color: #C40C72;">
                <a href="#apol_kidney"><img class="lozad" data-src="assets/images/apol1-kidney-disease.jpg" alt="APOL1 Kidney Diseas"></a>
                <div class="text">
                  <a class="pink_link" href="#apol_kidney">APOL1 Kidney Disease</a>
                </div>
              </div>
              <p>Learn about the APOL1 gene and how it increases your risk of getting chronic kidney disease</p>
            </div>
            <div class="swiper-slide">
              <div class="img" style="border-color: #255B7C;">
                <a href="#recognizing_symptoms"><img class="lozad" data-src="assets/images/recognizing-symptoms.jpg" alt="RECOGNIZING SYMPTOMS"></a>
                <div class="text">
                  <a class="pink_link" href="#recognizing_symptoms">RECOGNIZING SYMPTOMS</a>
                </div>
              </div>
              <p>Learn about the APOL1 gene and how it increases your risk of getting chronic kidney disease</p>
            </div>
            <div class="swiper-slide">
              <div class="img" style="border-color: pink;">
                <a href="#apol1_gene"><img class="lozad" data-src="assets/images/apol1-gene.jpg" alt="You, Your Family and the APOL1 Gene"></a>
                <div class="text">
                  <a class="pink_link" href="#apol1_gene">You, Your Family and the APOL1 Gene</a>
                </div>
              </div>
              <p>Learn about the APOL1 gene and how it increases your risk of getting chronic kidney disease</p>
            </div>
            <div class="swiper-slide">
              <div class="img" style="border-color: rgb(65, 147, 210);">
                <a href="#mazes_commitment"><img class="lozad" data-src="assets/images/comitment.jpg" alt="Maze's Commitment to You"></a>
                <div class="text">
                  <a class="pink_link" href="#mazes_commitment">Maze's Commitment to You</a>
                </div>
              </div>
              <p>Learn about the APOL1 gene and how it increases your risk of getting chronic kidney disease</p>
            </div>
            <div class="swiper-slide">
              <div class="img" style="border-color: rgb(65, 147, 210);">
                <a href="#advisary_committee"><img src="assets/images/maze-advisary.jpg" alt="Maze Patient Advisory Committee"></a>
                <div class="text">
                  <a class="pink_link" href="#advisary_committee">Maze Patient Advisory Committee</a>
                </div>
              </div>
              <p>Learn about the APOL1 gene and how it increases your risk of getting chronic kidney disease</p>
            </div>
          </div>
          <div class="swiper-pagination"></div>
        </div>
        <div class="swiper-button-prev">
          <img src="assets/images/left-arrow.svg" alt="left icon">
        </div>
        <div class="swiper-button-next">
          <img src="assets/images/right-arrow.svg" alt="right icon">
        </div>
      </div>

    </section>
    <div class="container">
      <b class="hr"></b>
    </div>
    <section id="apol1_origin" class="bg_contain" style="background-image: url('assets/images/origin-background.png');">
       <div class="container">
        <h2 class="heading" style="margin-bottom: 60px;">APOL1 and Its Origin</h2>
        <div class="row">
          <div class="left">
            <p>
              <span class="bullet"></span>
              Everyone has a gene called APOL1 or apolipoprotein L1. We each have two copies of the APOL1 gene, one inherited from each of our parents. 
            </p>
            <p>
              <span class="bullet"></span>
              Some people have changes in the APOL1 gene, known as variants or mutations, which increase their risk of developing chronic kidney disease.
              People of African ancestry, including those who identify as Black, African American, Caribbean, and/or Latino, who carry these APOL1 gene variants may experience faster loss of kidney function.
            </p>
          </div>
          <div class="right">
            <!-- <img class="lozad" data-src="assets/images/APOL1-Origin.png" alt="people"> -->
            <img class="lozad" data-src="assets/images/apolo-bottom.png" alt="People of African ancestry, including those who identify as Black, African American, Caribbean, and/or Latino/Latina, who have these gene variants are at a higher risk of developing APOL1 Kidney Disease">
          </div>
        </div>
        <p class="centered">
          <span class="bullet"></span>
          The APOL1 gene variants originally evolved in people who lived in
          Western and Central Africa, to protect them from a deadly disease known as
          African sleeping sickness. However, these same gene variants are now known to increase a person's risk of developing kidney disease.
        </p>
       </div>
    </section>
    <div class="container">
      <b class="hr"></b>
    </div>
    <section id="apol_kidney" class="bg_contain" style="background-image: url('assets/images/apol-kidney-bg@2x-8.png');">
      <div class="container">
        <h2 class="heading">APOL1 Kidney Disease</h2>
        <p class="sub_p">
          APOL1 Kidney Disease, also known as APOL1-mediated kidney disease (AMKD), refers to chronic kidney disease in patients with APOL1 gene variants and is linked to <span class="brand">several types of kidney disorders.</span> 
        </p>
        <img class="lozad" data-src="assets/images/kidney-disease.png" alt="diseases list">
      </div>
    </section>
    <div class="container">
      <b class="hr"></b>
    </div>
    <section id="recognizing_symptoms">
      <div class="container">
        <h2 class="heading">Recognizing Symptoms</h2>
        <p class="sub_p">Kidney diseases can show up in different ways. Symptoms for APOL1 Kidney Disease are similar to other kidney diseases. Common symptoms include: </p>
        <div class="img">
          <img class="lozad" data-src="assets/images/symptoms@2x-8.png" alt="symptoms">
        </div>
        <p class="sub_p">Some people may have one or more signs or symptoms. Others may not have any until their kidney disease is more advanced. That is why it is important to see a doctor and check your kidney function with simple urine and blood tests.</p>
      </div>
    </section>
    <div class="container">
      <b class="hr"></b>
    </div>
    <section id="apol1_gene" class="bg_contain" style="background-image: url('assets/images/family-bg@2x-8.png')">
      <div class="container">
        <h2 class="heading">You, Your Family, and the APOL1 Gene</h2>
        <img class="gene lozad" data-src="assets/images/gene@2x-8.png" alt="gene">
      </div>
        <div class="row bg_contain" style="background-image: url('assets/images/early-detection.png');">
          <div class="container">
            <div class="text" style="padding-bottom: 20px;">
              <p>APOL1 genetic testing provides valuable information about your health, your family's health, available treatment options, and potential eligibility for clinical trials.</p>
            </div>
          </div>
        </div>
        <div class="container" style="text-align: center;">
          <img class="lozad" style="max-width: 900px;" data-src="assets/images/family_points@2x-8.png" alt="points">
        </div>
    </section>
    <div class="container">
      <b class="hr"></b>
    </div>
    <section id="mazes_commitment">
      <div class="container">
        <h2 class="heading">
          Maze’s Commitment to You 
        </h2>
        <div class="text">
          <p>APOL1 Kidney Disease currently has no approved treatments, but there is a hope. To address this unmet need, Maze is developing a new oral medication called MZE829 as a potential therapy for APOL1 Kidney Disease.</p>
          <img class="lozad" style="object-fit: cover;" data-src="assets/images/maze-commitment-to-you.png" alt="meeting hands">
          <p>Along with the help of trusted patient advisors, physicians, and scientists, Maze has launched our Phase 2 Clinical Trial for APOL1 Kidney Disease. We are currently looking for individuals to join our trial. To get genetically tested for APOL1 and/or explore potential eligibility for clinical trials, please CLICKHERE (or CONTACT US).
          </p>
        </div>
        <img class="lozad bg_obj" data-src="assets/images/hands-bg@2x-8.png" alt="Background Object" >
      </div>
    </section>
    <div class="container">
      <b class="hr"></b>
    </div>
    <section id="advisary_committee">
      <div class="container">
        <h2 class="heading">
          Maze Patient Advisory Committee
        </h2>
        <p class="text sub_p">Maze is proud to partner with leaders and allies from the APOL1 Kidney Disease and Black chronic kidney disease (CKD) communities to create a Patient Advisory Committee for our APOL1 Kidney Disease Program. This committee ensures that the voices of patients are at the center of everything we do. By working together, we focus on making sure our clinical trials are patient centric, and support study access and participation.</p>
      </div>
      <div class="committee" class="bg_contain" style="background-image: url('assets/images/bg-users@2x-8.png')">
        <div class="container">
          <div class="users">
            <div class="user" >
              <img class="lozad" data-src="assets/images/pac1.JPG" alt="Curtis Warfield">
              <h6>Curtis Warfield</h6>
              <div class="title">Transplant Recipient <br> Patient Advocate for APOL1 </div>
            </div>
            <div class="user" >
              <img class="lozad" data-src="assets/images/pac2.png" alt="Glenda V. Roberts">
              <h6>Glenda V. Roberts</h6>
              <div class="title">Transplant Recipient  <br> Family history of kidney disease </div>
            </div>
            <div class="user" >
              <img class="lozad" data-src="assets/images/Sharron_Rouse.jpg" alt="Sharron Rouse">
              <h6>Sharron Rouse</h6>
              <div class="title">Transplant Recipient <br> APOL1 Kidney Disease Warrior </div>
            </div>
          </div>
        </div>
      </div>
    </section>
    <div class="container">
      <b class="hr"></b>
    </div>
    <section id="learn_more"  class="bg_contain" style="background-image: url('assets/images/apol-kidney-bg@2x-8.png');">
      <div class="container">
        <h2 class="heading">Learn More About APOL1 Kidney Disease 
          and MZE829</h2>
          <p class="highlight sub_p">Scroll through the history of APOL1 breakthroughs – From current developments for APOL1 Kidney Disease to early discovery of the APOL1 gene. Learn more.
          </p>
          <div class="tabs">
            <div class="tab">
              <h5>Maze completes a Phase 1 healthy volunteer trial studying the safety of their APOL1 inhibitor 
                (MZE829) in humans</h5>
                <p class="content"></p>
                <div class="full_content h-0">                  
                </div>
                <a class="read_more" href="#">Read more</a>
            </div>
            <div class="tab">
              <h5>Blocking APOL1 channel activity and reduces toxicity (2023)
              </h5>
                <p class="content"></p>
                <div class="full_content h-0">
                  <ul>
                    <li><em><u>Key References</u></em>:
                      <ul>
                        <li>o	Hung A. M. (2023). “Genetic inhibition of APOL1 pore-forming function prevents APOL1-mediated kidney disease.” Journal of the American Society of Nephrology.</li>
                      </ul>
                    </li>
                  </ul>               
                </div>
                <a class="read_more" href="#">Read more</a>
            </div>
            <div class="tab">
              <h5>Therapeutic development of APOL1 inhibitors (2018 – present)</h5>
                <p class="content"></p>
                <div class="full_content h-0">
                  <ul>
                    <li>
                      Maze begins studying APOL1 into order to develop transformative medicines for kidney disease (2018)
                    </li>
                    <li><em><u>Key References</u></em>:
                      <ul>
                        <li>FP-PO318 “MZ-301 Is a Small Molecule Inhibitor of APOL1 Pore Function That Attenuates Albuminuria in a Mouse Model of APOL1-Mediated Kidney Disease” – Maze abstract from 2022 </li>
                        <li>https://www.asn-online.org/education/kidneyweek/archives/KW23Abstracts.pdf (ASN 2023) 
                          SA-PO788 “Small Molecule Inhibition of APOL1 Reverses Albuminuria in a Chronic Mouse Model of APOL1-Mediated Kidney Disease” – Maze abstract from 2023</li>
                      </ul>
                    </li>
                  </ul>               
                </div>
                <a class="read_more" href="#">Read more</a>
            </div>
            <div class="tab">
              <h5>Mechanistic studies on APOL1 variants (2014 – 2022)</h5>
                <p class="content"></p>
                <div class="full_content h-0">
                  <ul>
                    <li>
                      APOL1 G1 and G2 variants lead to kidney disease through various cytotoxicity and cellular stress pathways. 
                    </li>
                    <li>APOL1 is a cation channel. </li>
                    <li><em><u>Key References</u></em>:
                      Key References:
                      <ul>
                        <li>Lan X. (2014). &ldquo;APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability.&rdquo; American Journal of Physiology-Renal Physiology.</li>
                        <li>Olabisi O. A. (2016). &ldquo;APOL1 Kidney Disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.&rdquo; Proceedings of the National Academy of Sciences.</li>
                        <li>Bruno J. (2017). &ldquo;Apolipoprotein L1 confers pH-switchable ion permeability to phospholipid vesicles.&rdquo; The Journal of Biological Chemistry.</li>
                        <li>Beckerman (2017). &ldquo;Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.&rdquo; Nature Medicine.</li>
                        <li>Giovinazzo J. A. (2020). &ldquo;Apolipoprotein L-1 renal risk variants form active channels at the plasma membrane driving cytotoxicity.&rdquo; eLife.</li>
                        </ul>
                    </li>
                  </ul>               
                </div>
                <a class="read_more" href="#">Read more</a>
            </div>
            <div class="tab">
              <h5>APOL1 variants in kidney transplantation outcomes (2011 – present)</h5>
                <p class="content">
                  <div class="full_content h-0">
                    <ul>
                      <li>
                      <ul>
                      <li>Kidneys from donors with two APOL1 risk alleles have a higher risk of graft failure post-transplantation, leading to more cautious donor selection processes.</li>
                      <li>Key References:
                      <ul>
                      <li>Reeves-Daniel A. M. (2011). &ldquo;The APOL1 gene and allograft survival after kidney transplantation.&rdquo; American Journal of Transplantation.</li>
                      <li>The APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) study was launched to better understand the impact of APOL1 variants on kidney transplant outcomes (ClinicalTrials.gov identifier: NCT03615235).</li>
                      </ul>
                      </li>
                      </ul>
                      </li>
                      </ul>              
                  </div>
                <a class="read_more" href="#">Read more</a>
            </div>
            <div class="tab">
              <h5>APOL1 variants in clinical disease studies (2011 – 2013)</h5>
                <p class="content">
                </p>
                <div class="full_content h-0">
                  <ul>
                    <li>Individuals with two APOL1 risk variants (G1/G1, G1/G2, or G2/G2) are at a significantly increased risk of developing FSGS, HIVAN, hypertensive nephrosclerosis, and other kidney diseases.</li>
                    <li>In individuals with two APOL1 risk alleles, kidney disease tends to progress more rapidly to ESRD, which explains the higher rates of kidney failure in African American populations.</li>
                    <li>Key References:
                    <ul>
                    <li>Kopp J. B. (2011). &ldquo;APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.&rdquo; Journal of the American Society of Nephrology.</li>
                    <li>Parsa A. (2013). &ldquo;APOL1 risk variants, race, and progression of chronic kidney disease.&rdquo; The New England Journal of Medicine.</li>
                    </ul>
                    </li>
                    </ul>                  
                </div>
                <a class="read_more" href="#">Read more</a>
            </div>
            <div class="tab">
              <h5>Discovery of APOL1 genetic variants and kidney disease (2010)</h5>
                <p class="content">
                </p>
                <div class="full_content h-0">
                  <ul>
                    <li>APOL1 variants, known as G1 and G2, are strongly associated with an increased risk of developing chronic kidney disease (CKD). These variants are more common in people of African descent and may explain higher rates of kidney disease in this population.</li>
                    <li><em><u>Key References</u></em>:
                    <ul>
                    <li>Genovese G. (2010). &ldquo;Association of trypanolytic ApoL1 variants with kidney disease in African Americans.&rdquo; Science.</li>
                    </ul>
                    </li>
                    </ul>                  
                </div>
                <a class="read_more" href="#">Read more</a>
            </div>
            <div class="tab">
              <h5>APOL1 and trypanosome resistance (2003)</h5>
                <p class="content">
                </p>
                <div class="full_content h-0">
                  <ul>
                    <li>APOL1 was found to have a critical role in innate immunity by conferring resistance to <em>Trypanosoma brucei</em>, the parasite responsible for African sleeping sickness. The APOL1 protein causes lysis of the parasite, which protects individuals from infection.</li>
                    <!-- <li><em><u>Key References</u></em>:
                    <ul>
                    <li>Vanhamme L., (2003). &ldquo;Apolipoprotein L-I is the trypanosome lytic factor of human serum.&rdquo; Nature.</li>
                    </ul>
                    </li> -->
                  </ul>                   
                </div>
                <a class="read_more" href="#">Read more</a>
            </div>
            <div class="tab">
              <h5>APOL1 gene and protein discovery (1997)</h5>
                <p class="content">
                </p>
                <div class="full_content h-0">
                  <ul>
                    <li>The APOL1 gene was identified as part of the apolipoprotein L gene family. This early discovery highlighted APOL1 as part of the high-density lipoprotein (HDL) complex.</li>
                    <!-- <li><em><u>Key References</u></em>:
                      <ul>
                        <li>Duchateau, P. N. (1997). &ldquo;Apolipoprotein L, a new human high-density lipoprotein apolipoprotein expressed by the pancreas.&rdquo; The Journal of Biological Chemistry.</li>
                      </ul>
                    </li> -->
                  </ul>                  
                </div>
                <a class="read_more" href="#">Read more</a>
            </div>
            <div class="tab">
              <h5>Pre-discovery period (1980s – 1900s)</h5>
                <p class="content">
                </p>
                <div class="full_content h-0">
                  <ul>
                    <li>Studies explored the resistance of certain African populations to African sleeping sickness, focusing on genetic factors that offered protection against <em>Trypanosoma brucei</em>.</li>
                    <li>Researchers hypothesized that blood serum factors in these populations had a role in lysing the parasite and preventing infection. However, the specific genes involved had not yet been identified.</li>
                    <!-- <li><em><u>Key References</u></em>:
                    <ul>
                    <li>Rifkin M. R. (1978). &ldquo;Trypanosoma brucei: some properties of the cytotoxic reaction induced by normal human serum.&rdquo; Experimental Parasitology.</li>
                    <li>Hajduk S. L. (1989). &ldquo;Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein.&rdquo; The Journal of Biological Chemistry.</li>
                    <li>Tomlinson S. (1996). &ldquo;The lysis of <em>Trypanosoma brucei brucei</em> by human serum.&rdquo; Nature Biotechnology.</li>
                    </ul>
                    </li> -->
                    </ul>                
                </div>
                <a class="read_more" href="#">Read more</a>
            </div>

          </div>
      </div>
    </section>
    <div class="container">
      <b class="hr"></b>
    </div>
    <section id="maze_affliations">
      <div class="container">
        <h2 class="heading">Maze Patient Advocacy Affiliations</h2>
          <div class="brands">
            <a target="_blank" href="https://www.kidneyfund.org/" style="max-width: 500px; margin: auto;">
              <img class="lozad sub_padding" data-src="assets/images/affiliations-2 (1).png" alt="American Kidney Fund">
            </a>
          </div>
      </div>
    </section>

    <footer>
      <div class="container">
        <div class="row">
          <div class="left">
            <h4><a target="_blank" href="https://mazetx.com/">Maze Therapeutics</a></h4>
          </div>
          <div class="right">
            <ul>
              <li>
                <a>© 2024 Maze Therapeutics</a>
              </li>
              <li>
                <a target="_blank" href="https://mazetx.com/privacy-notice/">Privacy Notice</a>
              </li>
              <li>
                <a target="_blank" href="https://mazetx.com/terms-of-use/">Terms of Use</a>
              </li>
            </ul>
          </div>
        </div>
      </div>
      <a class="top-link hide" href="" id="js-top">
        <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><!--!Font Awesome Free 6.6.0 by @fontawesome - https://fontawesome.com License - https://fontawesome.com/license/free Copyright 2024 Fonticons, Inc.--><path d="M201.4 137.4c12.5-12.5 32.8-12.5 45.3 0l160 160c12.5 12.5 12.5 32.8 0 45.3s-32.8 12.5-45.3 0L224 205.3 86.6 342.6c-12.5 12.5-32.8 12.5-45.3 0s-12.5-32.8 0-45.3l160-160z"/></svg>
        <span class="screen-reader-text">Back to top</span>
      </a>
    </footer>

    <script>
      const observer = lozad(); // lazy loads elements with default selector as '.lozad'
      observer.observe();
    </script>
    <!-- Swiper Js -->
    <script src="https://cdn.jsdelivr.net/npm/swiper@11/swiper-bundle.min.js"></script>



    <!-- Optional JavaScript -->
    <script src="assets/js/script.js"></script>

  </body>
</html>